Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s ...
Biomea Fusion: Recent Rally May Not Last, Despite Upcoming Data Catalysts
I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...
Buy Rating Affirmed for Biomea Fusion with Promising BMF-219 Clinical and Regulatory Developments
Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...
US FDA lifts clinical hold on Biomea’s diabetes trials after safety review
The drug BMF-219 works by increasing, preserving and reactivating patients’ own healthy insulin-producing cells. Read more at ...
Biomea upgraded by analysts after FDA lifts clinical hold
Biomea (BMEA) has received two analyst upgrades along with bullish comments from other firms following news the FDA has lifted a clinical hold on a study of its drug BMF-219.
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 1 and type 2 diabetes following a safety review, ...
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected
U.S. stocks traded mixed midway through trading, with the Dow Jones index surging more than 250 points on Friday. The Dow ...
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Friday. Shares of IonQ, Inc. (NASDAQ:IONQ) ...
Pharmaceutical Technology6d
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, ...
FierceBiotech6d
FDA lifts hold on diabetes trials after Biomea mitigates liver toxicity risk
Biomea Fusion has escaped from the full clinical hold imposed by the FDA. | Biomea Fusion has escaped from the full clinical hold imposed by the FDA. After reviewing the data, the regulator has ...
Biomea Fusion, Inc.: FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing ...